Prepn: S. Sanczuk, H. K. F. Hermans, DE 2642856 (1977 to Janssen), C.A. 87, 53094 (1977); eidem, US 4126689 (1978 to Janssen). Determn of lorcainide and its metabolites by GLC: R. Woestenborghs et al., J. Chromatogr. 164, 169 (1979). Disposition and anti-arrhythmic effects: U. Klotz et al., Int. J. Clin. Pharmacol. Biopharm. 17, 152 (1979). Pharmacokinetics and tissue distribution: U. Klotz, E. Golbs, Arzneim.-Forsch. 30, 619 (1980). Clinical study: P. Somani, S. di Giorgi, Chest 78, 658 (1980). Toxicology: G. J. Barton, R. Marsboom, “A Brief Summary of Animal Toxicology Studies on Lorcainide”, in Prognosis and Pharmacotherapy of Life-Threatening Arrhythmias, Jhnchen et al., Eds. (Royal Soc. Med. London, 1981) pp 23-25. Review of pharmacology and efficacy: C. E. Eriksson, R. N. Brogden, Drugs 27, 279-300 (1984). Symposium: Am. J. Cardiol. 54, 1B-54B (1984).
Antiarrhythmic (class IC).
Antiarrhythmic